232 related articles for article (PubMed ID: 11395971)
1. The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis.
Tanner JE; Alfieri C
Transpl Infect Dis; 2001 Jun; 3(2):60-9. PubMed ID: 11395971
[TBL] [Abstract][Full Text] [Related]
2. The biology of Epstein-Barr virus in post-transplant lymphoproliferative disease.
Hsieh WS; Lemas MV; Ambinder RF
Transpl Infect Dis; 1999 Sep; 1(3):204-12. PubMed ID: 11428990
[TBL] [Abstract][Full Text] [Related]
3. The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.
Martinez OM; Krams SM
Transplantation; 2017 Sep; 101(9):2009-2016. PubMed ID: 28376031
[TBL] [Abstract][Full Text] [Related]
4. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS
Front Immunol; 2020; 11():1231. PubMed ID: 32625211
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus: evasive maneuvers in the development of PTLD.
Snow AL; Martinez OM
Am J Transplant; 2007 Feb; 7(2):271-7. PubMed ID: 17229074
[TBL] [Abstract][Full Text] [Related]
6. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
[TBL] [Abstract][Full Text] [Related]
7. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice.
Caduff N; McHugh D; Murer A; Rämer P; Raykova A; Landtwing V; Rieble L; Keller CW; Prummer M; Hoffmann L; Lam JKP; Chiang AKS; Raulf F; Azzi T; Berger C; Rubic-Schneider T; Traggiai E; Lünemann JD; Kammüller M; Münz C
PLoS Pathog; 2020 Apr; 16(4):e1008477. PubMed ID: 32251475
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting.
Paya CV; Fung JJ; Nalesnik MA; Kieff E; Green M; Gores G; Habermann TM; Wiesner PH; Swinnen JL; Woodle ES; Bromberg JS
Transplantation; 1999 Nov; 68(10):1517-25. PubMed ID: 10589949
[TBL] [Abstract][Full Text] [Related]
10. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
Dolcetti R
Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317
[TBL] [Abstract][Full Text] [Related]
11. Genomic variations in EBNA3C of EBV associate with posttransplant lymphoproliferative disorder.
Maloney EM; Busque VA; Hui ST; Toh J; Fernandez-Vina M; Krams SM; Esquivel CO; Martinez OM
JCI Insight; 2020 Mar; 5(6):. PubMed ID: 32213705
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment.
Overkamp M; Granai M; Bonzheim I; Steinhilber J; Schittenhelm J; Bethge W; Quintanilla-Martinez L; Fend F; Federmann B
Virchows Arch; 2021 Jun; 478(6):1135-1148. PubMed ID: 33324999
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus (EBV)-positive lymphoproliferations in post-transplant patients show immunoglobulin V gene mutation patterns suggesting interference of EBV with normal B cell differentiation processes.
Bräuninger A; Spieker T; Mottok A; Baur AS; Küppers R; Hansmann ML
Eur J Immunol; 2003 Jun; 33(6):1593-602. PubMed ID: 12778477
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus, rapamycin, and host immune responses.
Krams SM; Martinez OM
Curr Opin Organ Transplant; 2008 Dec; 13(6):563-8. PubMed ID: 19060543
[TBL] [Abstract][Full Text] [Related]
15. Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment.
Petrara MR; Giunco S; Serraino D; Dolcetti R; De Rossi A
Cancer Lett; 2015 Dec; 369(1):37-44. PubMed ID: 26279520
[TBL] [Abstract][Full Text] [Related]
16. Interferon-alpha and its effects on post-transplant lymphoproliferative disorders.
Faro A
Springer Semin Immunopathol; 1998; 20(3-4):425-36. PubMed ID: 9870255
[TBL] [Abstract][Full Text] [Related]
17. In vivo intratumoral Epstein-Barr virus replication is associated with XBP1 activation and early-onset post-transplant lymphoproliferative disorders with prognostic implications.
Gonzalez-Farre B; Rovira J; Martinez D; Valera A; Garcia-Herrera A; Marcos MA; Sole C; Roue G; Colomer D; Gonzalvo E; Ribera-Cortada I; Araya M; Lloreta J; Colomo L; Campo E; Lopez-Guillermo A; Martinez A
Mod Pathol; 2014 Dec; 27(12):1599-611. PubMed ID: 24762547
[TBL] [Abstract][Full Text] [Related]
18. Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases.
Babel N; Gabdrakhmanova L; Hammer M; Rosenberger C; Oppert M; Volk HD; Reinke P
Transpl Infect Dis; 2005; 7(3-4):133-6. PubMed ID: 16390402
[TBL] [Abstract][Full Text] [Related]
19. Determining virological, serological and immunological parameters of EBV infection in the development of PTLD.
Davis JE; Sherritt MA; Bharadwaj M; Morrison LE; Elliott SL; Kear LM; Maddicks-Law J; Kotsimbos T; Gill D; Malouf M; Falk MC; Khanna R; Moss DJ
Int Immunol; 2004 Jul; 16(7):983-9. PubMed ID: 15159377
[TBL] [Abstract][Full Text] [Related]
20. Post-transplant lymphoproliferative disorder.
Basgoz N; Preiksaitis JK
Infect Dis Clin North Am; 1995 Dec; 9(4):901-23. PubMed ID: 8747772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
